Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SIM0270 + everolimus
- Development stage
- Phase 3
- Lead developer
- Jiangsu Simsheng Pharmaceutical
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules
- Administration
- Oral
01
Overview
SIM0270 + everolimus is an investigational oral combination therapy for the treatment of estrogen receptor-positive, HER2-negative (ER+/HER2-) locally advanced or metastatic breast cancer. SIM0270 is a novel, brain-penetrant, oral selective estrogen receptor degrader (SERD) designed to degrade the estrogen receptor and overcome resistance to prior endocrine therapies. Everolimus is a well-established mammalian target of rapamycin (mTOR) inhibitor that disrupts cellular growth and proliferation pathways. The combination aims to leverage potential synergistic effects by targeting both ER signaling and mTOR pathways, addressing limited efficacy seen with current endocrine therapies in patients who have progressed after CDK4/6 inhibitors or other standard treatments[1][3][4][5][7].
02
Targets
ER (Estrogen receptor)mTOR (Mammalian target of rapamycin kinase)
Beyond the preview
Go deeper on SIM0270 + everolimus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SIM0270 + everolimus.